Bifidobacterium adolescentis was isolated from intestine of adult. It is the normal inhabitant of healthy human and animal intestinal tracts.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
CAT | Size | Price | Quantity | |
---|---|---|---|---|
LBST-058FG |
|
Product Information | |
---|---|
Product Overview | Bifidobacterium adolescentis was isolated from intestine of adult. It is the normal inhabitant of healthy human and animal intestinal tracts. |
Target | Bifidobacterium |
Genus | Bifidobacterium |
Application | Study and research |
Type Strain | Yes |
Culture Medium | BBL |
Culture Conditions | 37°C; Anaerobic |
Source | Intestine of adult |
Risk Group | 1 |
Product Format | Freeze-dried |
Packaging | Ampoule tube |
Storage | -80°C |
Shelf Life | 6 years |
Target Introduction | |
---|---|
Introduction | Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS; Generally Recognised As Safe status. |
Alternative Names | Bifidobacterium adolescentis; 134301 |
To ensure the viability of Bifidobacterium adolescentis, it should be stored at -80°C in cryoprotectant media. Avoid repeated freeze-thaw cycles, as they can significantly reduce bacterial viability. Proper storage conditions are crucial for maintaining the integrity and functionality of the bacterial cells for research purposes.
Before use in in vitro experiments, Bifidobacterium adolescentis should be rehydrated from its lyophilized form using an appropriate anaerobic growth medium. The culture should be incubated under anaerobic conditions at 37°C until reaching the desired cell density. Proper handling ensures the bacteria's viability and activity during experimental procedures.
Bifidobacterium adolescentis has been shown to modulate the host's immune response by promoting the production of anti-inflammatory cytokines and enhancing the activity of regulatory T cells. This strain helps maintain gut homeostasis and may contribute to the prevention of inflammatory diseases.
For animal studies, the recommended concentration of Bifidobacterium adolescentis varies depending on the experimental design. Typically, a dose ranging from 10^7 to 10^9 colony-forming units (CFU) per gram of diet or per milliliter of suspension is used. This dosage is adjusted based on the specific research objectives and the animal model employed.
Quality control measures for Bifidobacterium adolescentis include verifying the strain identity through genetic sequencing, ensuring the absence of contaminants, and assessing the viability and concentration of the bacteria. Regular testing and adherence to Good Manufacturing Practices ensure the consistency and reliability of research results.
Click the button below to contact us or submit your feedback about this product.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2024 Creative Biolabs. All Rights Reserved.